BAYER AG-REG (BAYN.DE) Stock Price, Forecast & Analysis
Europe - FRA:BAYN - DE000BAY0017 - Common Stock
BAYN.DE Key Statistics, Chart & Performance
The current stock price of BAYN.DE is 26.055 EUR. In the past month the price decreased by -6.88%. In the past year, price increased by 8.2%.
BAYN.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 11.24 | 208.13B | ||
| SNW.DE | SANOFI | 11.24 | 208.11B | ||
| MRK.DE | MERCK KGAA | 12.86 | 47.59B | ||
| UCB.BR | UCB SA | 35.31 | 44.10B | ||
| 1BAYN.MI | BAYER AG-REG | 5.28 | 26.00B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.24 | 10.40B | ||
| IPN.PA | IPSEN | 12.05 | 10.38B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 97.84 | 9.06B | ||
| VIRP.PA | VIRBAC SA | 19.9 | 2.89B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 16.58 | 1.78B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 1.05B | ||
| 9VC.DE | ATAI LIFE SCIENCES NV | N/A | 861.29M |
Related stock screener links
About BAYN.DE
Company Profile
Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 89,556 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
Company Info
BAYER AG-REG
Kaiser-Wilhelm-Allee 1
Leverkusen NORDRHEIN-WESTFALEN DE
Employees: 90587
Phone: 49214301
BAYER AG-REG / BAYN.DE FAQ
What does BAYN do?
Bayer AG engages in the business of life science fields of healthcare and nutrition. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 89,556 full-time employees. The firm's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.
What is the current price of BAYN stock?
The current stock price of BAYN.DE is 26.055 EUR. The price decreased by -1.72% in the last trading session.
Does BAYER AG-REG pay dividends?
BAYER AG-REG (BAYN.DE) has a dividend yield of 0.41%. The yearly dividend amount is currently 0.13.
What is the ChartMill technical and fundamental rating of BAYN stock?
BAYN.DE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy BAYN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BAYN.DE.
What is BAYER AG-REG worth?
BAYER AG-REG (BAYN.DE) has a market capitalization of 25.60B EUR. This makes BAYN.DE a Large Cap stock.
BAYN.DE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BAYN.DE. When comparing the yearly performance of all stocks, BAYN.DE turns out to be only a medium performer in the overall market: it outperformed 54.81% of all stocks.
BAYN.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BAYN.DE. BAYN.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
BAYN.DE Financial Highlights
Over the last trailing twelve months BAYN.DE reported a non-GAAP Earnings per Share(EPS) of 5.01. The EPS decreased by -16.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.25% | ||
| ROE | -11.25% | ||
| Debt/Equity | 1.04 |
BAYN.DE Forecast & Estimates
28 analysts have analysed BAYN.DE and the average price target is 29.07 EUR. This implies a price increase of 11.57% is expected in the next year compared to the current price of 26.055.
For the next year, analysts expect an EPS growth of -6.5% and a revenue growth -1.37% for BAYN.DE